Clinical trial
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral…
NCT00217425 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00217425 |
|---|---|
| Title | Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms |
| Official title | Bevacizumab and CHOP (A-CHOP) in Combination for Patients With Peripheral T-Cell or Natural Killer Cell Neoplasms |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine |
| Enrollment | 46 |
| Start date | Sep 14, 2006 |
| Primary completion | Apr 1, 2012 |
| Completion | Mar 1, 2014 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 18, 2023 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: